PhaseRx (PZRX) IPO Opens Up 10%

Today's IPO for PhaseRx, Inc. (NASDAQ: PZRX) opened for trading at $5.50 after pricing 3,700,000 shares of common stock at an initial public offering price of $5.00.

Laidlaw & Company (UK) Ltd. and Roth Capital Partners are acting as joint book-running managers for the offering.

PhaseRx is a preclinical biopharmaceutical company dedicated to developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). The Company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle, Wash.

You May Also Be Interested In

• Scribe Therapeutics files for proposed Nasdaq IPO
• InvestorNewsBreaks – Alpex Acquisition Corporation (NASDAQ: ALPXU) Closes $115 Million Initial Public Offering
• ITG, Inc. raises $323.4M in Nasdaq IPO at $16 per share